Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
Status: Enrolling
Updated:  7/27/2017
BLI Research Site 21
mi
from
Salt Lake City, UT
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
Status: Enrolling
Updated: 7/27/2017
BLI Research Site 21
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
Status: Enrolling
Updated:  7/27/2017
BLI Research Site 26
mi
from
Norfolk, VA
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
Status: Enrolling
Updated: 7/27/2017
BLI Research Site 26
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
Status: Enrolling
Updated:  7/27/2017
BLI Research Site 25
mi
from
Spokane, WA
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
Status: Enrolling
Updated: 7/27/2017
BLI Research Site 25
mi
from
Spokane, WA
Click here to add this to my saved trials
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
Status: Enrolling
Updated:  7/27/2017
BLI Research Site 59
mi
from
Port Saint Lucie, FL
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
Status: Enrolling
Updated: 7/27/2017
BLI Research Site 59
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
Status: Enrolling
Updated:  7/27/2017
BLI Research Site 15
mi
from
Saint Petersburg, FL
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
Status: Enrolling
Updated: 7/27/2017
BLI Research Site 15
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis
LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis: A Prospective, Randomized, Controlled Study
Status: Enrolling
Updated:  8/1/2017
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis
LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis: A Prospective, Randomized, Controlled Study
Status: Enrolling
Updated: 8/1/2017
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Topical Ruxolitinib for the Treatment of Vitiligo
Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo
Status: Enrolling
Updated:  8/1/2017
Tufts Medical Center
mi
from
Boston, MA
Topical Ruxolitinib for the Treatment of Vitiligo
Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo
Status: Enrolling
Updated: 8/1/2017
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Open-label Pilot Study of Abatacept for the Treatment of Vitiligo
Open-label Pilot Study of Abatacept for the Treatment of Vitiligo
Status: Enrolling
Updated:  8/8/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Open-label Pilot Study of Abatacept for the Treatment of Vitiligo
Open-label Pilot Study of Abatacept for the Treatment of Vitiligo
Status: Enrolling
Updated: 8/8/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Psychological Treatments for Scleroderma
Psychosocial Interventions for Scleroderma
Status: Enrolling
Updated:  8/8/2017
Johns Hopkins Bayview Medical Center
mi
from
Baltimore, MD
Psychological Treatments for Scleroderma
Psychosocial Interventions for Scleroderma
Status: Enrolling
Updated: 8/8/2017
Johns Hopkins Bayview Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cosmetic Study of AO+Mist in Improving the Appearance of Skin Afflicted With Keratosis Pilaris
A Placebo-Controlled, Double-Blind, Bi-Lateral Study to Evaluate the Performance and Tolerability of a Cosmetic Product Designed to Improve the Appearance of Skin Afflicted With Keratosis Pilaris
Status: Enrolling
Updated:  8/8/2017
SkinCare Physicians
mi
from
Chestnut Hill, MA
Cosmetic Study of AO+Mist in Improving the Appearance of Skin Afflicted With Keratosis Pilaris
A Placebo-Controlled, Double-Blind, Bi-Lateral Study to Evaluate the Performance and Tolerability of a Cosmetic Product Designed to Improve the Appearance of Skin Afflicted With Keratosis Pilaris
Status: Enrolling
Updated: 8/8/2017
SkinCare Physicians
mi
from
Chestnut Hill, MA
Click here to add this to my saved trials
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
A Randomized, Double-Blind, Placebo-Controlled Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
Status: Enrolling
Updated:  8/16/2017
Clinical Research Facility
mi
from
Chicago, IL
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
A Randomized, Double-Blind, Placebo-Controlled Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
Status: Enrolling
Updated: 8/16/2017
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
A Randomized, Double-Blind, Placebo-Controlled Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
Status: Enrolling
Updated:  8/16/2017
Clinical Research Facility
mi
from
Boston, MA
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
A Randomized, Double-Blind, Placebo-Controlled Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
Status: Enrolling
Updated: 8/16/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
A Randomized, Double-Blind, Placebo-Controlled Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
Status: Enrolling
Updated:  8/16/2017
Clinical Research Facility
mi
from
New York, NY
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
A Randomized, Double-Blind, Placebo-Controlled Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
Status: Enrolling
Updated: 8/16/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Texting Atopic Dermatitis Patients to Optimize Learning and EASI Scores
Texting Atopic Dermatitis Patients to Optimize Learning and EASI Scores
Status: Enrolling
Updated:  8/21/2017
Columbia University Medical Center / Department of Dermatology
mi
from
New York, NY
Texting Atopic Dermatitis Patients to Optimize Learning and EASI Scores
Texting Atopic Dermatitis Patients to Optimize Learning and EASI Scores
Status: Enrolling
Updated: 8/21/2017
Columbia University Medical Center / Department of Dermatology
mi
from
New York, NY
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Parkland Memorial Hospital
mi
from
Dallas, TX
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Parkland Memorial Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Palo Alto Medical Foundation-Gynecologic Oncology
mi
from
Mountain View, CA
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Palo Alto Medical Foundation-Gynecologic Oncology
mi
from
Mountain View, CA
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Stanford Cancer Institute
mi
from
Palo Alto, CA
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Stanford Cancer Institute
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Olive View-University of California Los Angeles Medical Center
mi
from
Sylmar, CA
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Olive View-University of California Los Angeles Medical Center
mi
from
Sylmar, CA
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Colorado Gynecologic Oncology Group
mi
from
Aurora, CO
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Colorado Gynecologic Oncology Group
mi
from
Aurora, CO
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
The Hartford Hospital
mi
from
Hartford, CT
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
The Hospital of Central Connecticut
mi
from
New Britain, CT
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Memorial University Medical Center
mi
from
Savannah, GA
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Memorial University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Northwestern University
mi
from
Chicago, IL
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Borgess Medical Center
mi
from
Kalamazoo, MI
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Borgess Medical Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Virtua Memorial
mi
from
Mount Holly, NJ
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Virtua Memorial
mi
from
Mount Holly, NJ
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Virtua Voorhees
mi
from
Voorhees, NJ
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Virtua Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
State University of New York - Downstate Medical Center
mi
from
Brooklyn, NY
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
State University of New York - Downstate Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Gynecologic Oncology Network
mi
from
Greenville, NC
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Gynecologic Oncology Network
mi
from
Greenville, NC
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
University of Cincinnati/Barrett Cancer Center
mi
from
Cincinnati, OH
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
University of Cincinnati/Barrett Cancer Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Abington Memorial Hospital
mi
from
Abington, PA
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Carilion Clinic Gynecological Oncology
mi
from
Roanoke, VA
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Carilion Clinic Gynecological Oncology
mi
from
Roanoke, VA
Click here to add this to my saved trials
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated:  8/23/2017
Odette Cancer Centre- Sunnybrook Health Sciences Centre
mi
from
Toronto,
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia
Status: Enrolling
Updated: 8/23/2017
Odette Cancer Centre- Sunnybrook Health Sciences Centre
mi
from
Toronto,
Click here to add this to my saved trials
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Status: Enrolling
Updated:  8/23/2017
Carolinas Medical Center NorthEast Medical Arts Building
mi
from
Concord, NC
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Status: Enrolling
Updated: 8/23/2017
Carolinas Medical Center NorthEast Medical Arts Building
mi
from
Concord, NC
Click here to add this to my saved trials
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Status: Enrolling
Updated:  8/23/2017
Dermatology Group of the Carolinas
mi
from
Concord, NC
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Status: Enrolling
Updated: 8/23/2017
Dermatology Group of the Carolinas
mi
from
Concord, NC
Click here to add this to my saved trials
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Status: Enrolling
Updated:  8/23/2017
Ada Jenkins Center
mi
from
Davidson, NC
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Status: Enrolling
Updated: 8/23/2017
Ada Jenkins Center
mi
from
Davidson, NC
Click here to add this to my saved trials
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Status: Enrolling
Updated:  8/23/2017
Harrisburg Sleep Center
mi
from
Harrisburg, NC
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Status: Enrolling
Updated: 8/23/2017
Harrisburg Sleep Center
mi
from
Harrisburg, NC
Click here to add this to my saved trials
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Status: Enrolling
Updated:  8/23/2017
Lake Norman Community Health Clinic
mi
from
Huntersville, NC
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Status: Enrolling
Updated: 8/23/2017
Lake Norman Community Health Clinic
mi
from
Huntersville, NC
Click here to add this to my saved trials
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Status: Enrolling
Updated:  8/23/2017
Kannapolis Internal Medicine
mi
from
Kannapolis, NC
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Status: Enrolling
Updated: 8/23/2017
Kannapolis Internal Medicine
mi
from
Kannapolis, NC
Click here to add this to my saved trials
Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris
A Split-face, Paired-comparison Pilot Study to Evaluate the Safety and Efficacy of Topical Benzoyl Peroxide 2.5% Cream Alone Versus Benzoyl Peroxide 2.5% Cream Plus Moisturizing Lotion for Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated:  8/28/2017
Northwestern University Department of Dermatology
mi
from
Chicago, IL
Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris
A Split-face, Paired-comparison Pilot Study to Evaluate the Safety and Efficacy of Topical Benzoyl Peroxide 2.5% Cream Alone Versus Benzoyl Peroxide 2.5% Cream Plus Moisturizing Lotion for Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated: 8/28/2017
Northwestern University Department of Dermatology
mi
from
Chicago, IL
Click here to add this to my saved trials